

Adverse event discontinuations

Dosing (mg)	Number of trials	Number (%) with outcome		Relative risk (95% CI)	NNH (95% CI)
		Sildenafil	Placebo		
25	3	2/312 (0.6)	3/426 (0.7)	0.9 (0.2 to 4.3)	
50	5	1/508 (0.2)	3/607 (0.5)	0.7 (0.2 to 2.8)	
100	5	5/506 (1.0)	3/607 (0.5)	1.6 (0.5 to 5.0)	
200	2	8/191 (4.2)	0/181 (0)		
Dose optimised	5	6/517 (1.2)	3/524 (0.6)	1.7 (0.5 to 5.3)	